TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04182932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 EV71 vaccine A dose
Description: Inactivated vaccine against EV71, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 EV71 vaccine B dose
Description: Inactivated vaccine against EV71, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 CVA16 vaccine C dose
Description: Inactivated vaccine against CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 CVA16 vaccine D dose
Description: Inactivated vaccine against CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 Bivalent vaccine E dose
Description: Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJ-40010 Bivalent vaccine high dose
Description: Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval
Study: NCT04390490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor
Description: Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
Study: NCT00762437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeltiq Dermal Cooling Device
Description: Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT03088072

Intervention type: DRUG
Group type: OTHER
Intervention: Edoxaban
Description: Edoxaban 60mg once daily in patients with CrCl \>50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow \<5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.

Intervention type: DEVICE
Group type: OTHER
Intervention: WATCHMAN LAA Closure
Description: Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin and Clopidogrel
Description: If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit.

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin and Warfarin
Description: If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
Study: NCT00841113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abarelix
Description: 100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin plus Bicalutamide
Description: Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
Study: NCT04182932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, three doses, 28 days interval
Study: NCT01864902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART33 cells
Description: genetically modified lymphocyte therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CART

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD33 CAR T cells
Study: NCT02537613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
Study: NCT01780922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Cranberry Juice Cocktail
Description: Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry Extract Beverage
Description: Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Cranberry Beverage
Description: Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
Study: NCT02537613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib given once daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib given once daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib given once daily by mouth
Study: NCT04299568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti gravity treadmill training
Description: Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
Study: NCT02480673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia
Description: The subject will eat 25 gr of chia in 2 oatmeal cookies at day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia
Description: The subject will eat 25 gr of chia in 2 oatmeal cookies at day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal
Description: The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normocaloric diet
Description: The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normocaloric diet
Description: The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normocaloric diet
Description: The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
Study: NCT01753310

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
Study: NCT03321747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: Treatments shall not be delivered more frequently than every other day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: Treatments shall not be delivered more frequently than every other day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: Treatments shall not be delivered more frequently than every other day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: Treatments shall not be delivered more frequently than every other day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: Treatments shall not be delivered more frequently than every other day.
Study: NCT02539030

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: simple microfracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture
Description: simple microfracture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartiFill
Description: add collagen when doing microfracture
Study: NCT01034137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: orally weekly in ascending dosages, starting at 10mg/week
Study: NCT04169737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT01034137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: orally weekly in ascending dosages, starting at 10mg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo MTX
Description: orally weekly
Study: NCT04169737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03339050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health for Hearts United
Description: The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
Study: NCT00127075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nomegestrol acetate
Description: 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol
Description: 75 mcg, once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo treatments
Study: NCT05234827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Total time duration for session is 40 minutes which includes 5 min of warm exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 minutes of VR session and 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
Study: NCT01753310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up to 2mL
Study: NCT02011633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 500/10mg
Description: 500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1201 500/10mg
Description: 500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin SR 500mg
Description: Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Study: NCT05234827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group receive endurance exercise testing in which stationary cycle is used for 30 min per session. It includes lower extremity strengthening i.e., increases hamstring and quadricep strength. Total time duration for session is 40 minutes in which 5 min of warm up exercises which include heel raises, arm circles, side leg raises, trunk rotation, elbow flexion and extension, knee flexion and extension, and shoulder internal and external rotation, 30 min of bicycling and after that 5-7 min of cool down exercises which include full body stretches i.e., toe touching, pectoralis major stretch, side by side bending, quadricep stretch, hamstring stretch, trapezius stretch and deep breathing.
Study: NCT02630264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatins
Description: Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~1. Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~2. Swirl gently. Do NOT shake.~Method of administration~1. E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~2. After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~3. Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction.
Study: NCT01541228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source
Description: Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source
Description: Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval.
Study: NCT01034137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo TCZ
Description: iv every 4 weeks
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Universal
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance Special
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Super Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Lite
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Universal
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Extra
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlance Plus Special
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.
Study: NCT01034137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks
Study: NCT03843177

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be performed. Only assessment will be done.
Study: NCT01759537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankylos dental endosseous implants-Sub-crestal
Description: Implants placed subcrestally

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankylos dental endosseous implants-Epi-crestal
Description: Implants placed Epi-crestally
Study: NCT03999125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept,
Description: Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab Injection
Description: Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex Drug Implant Product
Description: Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
Study: NCT00248339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon-alpha-2b (PEG-Intron)
Description: PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin \~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, \~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, \~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
Study: NCT03752229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolance Micro Flow
Description: Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler.